id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-E-0283-0008,FDA,FDA-2002-E-0283,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-09-30T18:25:49Z,,0,0,090000648049ea96
FDA-2002-E-0283-0009,FDA,FDA-2002-E-0283,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-09-30T18:39:15Z,,0,0,090000648049ea99
FDA-2002-E-0283-0006,FDA,FDA-2002-E-0283,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-09-30T18:23:05Z,,0,0,090000648049ea90
FDA-2002-E-0283-0005,FDA,FDA-2002-E-0283,Application for Patent Term Extension from Novartis Corporation,Other,Application,2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-09-30T18:20:23Z,,0,0,090000648049ea7f
FDA-2002-E-0283-0007,FDA,FDA-2002-E-0283,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-10-16T23:56:40Z,,0,0,090000648049ea94
FDA-2002-E-0283-0010,FDA,FDA-2002-E-0283,Letter from Novartis to FDA DMB,Other,Letter(s),2009-02-25T05:00:00Z,2009,2,2009-02-25T05:00:00Z,,2025-10-16T23:58:39Z,,0,0,090000648049ea9d